Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
HealthyVasodilationInsulin ResistanceAutonomic DysfunctionObesity
Interventions
OTHER

Carbon dioxide breathing

Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.

OTHER

Neurovascular Coupling

Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.

DRUG

Human insulin

Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.

Trial Locations (1)

65211

University of Missouri, Columbia

All Listed Sponsors
lead

University of Missouri-Columbia

OTHER